Home › Blog › Acetaminophen vs Ibuprofen

Ozempic vs Mounjaro vs Wegovy: Cost, Weight Loss & Insurance (2026)

March 12, 2026 · 7 min read

```html GLP-1 Weight Loss Drugs Comparison 2026

Complete Comparison of GLP-1 Weight Loss Drugs in 2026

Note: GLP-1 receptor agonists and GIP/GLP-1 receptor agonists have become increasingly popular for weight loss management. This comprehensive comparison covers the four leading medications available in 2026, with pricing, efficacy, and insurance information updated to reflect current market conditions.

Overview of GLP-1 Weight Loss Medications

Glucagon-like peptide-1 (GLP-1) receptor agonists and GIP/GLP-1 receptor agonists are medications that were originally developed to treat type 2 diabetes. Their remarkable weight loss benefits have led to FDA approval for chronic weight management in individuals with obesity or overweight with weight-related conditions. These medications work by regulating appetite, increasing feelings of fullness, and slowing gastric emptying.

As of 2026, the pharmaceutical landscape includes two semaglutide formulations (Ozempic and Wegovy) and two tirzepatide formulations (Mounjaro and Zepbound). Understanding the differences, costs, and coverage options is essential for patients considering these treatments.

Drug Comparison Table

Medication Active Ingredient FDA Approved Use Retail Price/Month With Insurance Average Weight Loss % Injection Frequency
Ozempic Semaglutide Type 2 Diabetes $900-$1,100 $50-$250/month 4-6% Weekly
Wegovy Semaglutide Chronic Weight Management $1,200-$1,550 $0-$500/month 10-15% Weekly
Mounjaro Tirzepatide Type 2 Diabetes $1,000-$1,300 $50-$300/month 6-8% Weekly
Zepbound Tirzepatide Chronic Weight Management $1,400-$1,700 $0-$550/month 20-22% Weekly

For more detailed information about GLP-1 medications, visit our comprehensive guide: Weight Loss Drugs Compared

To learn more about Ozempic specifically, see: Ozempic Details and Information

Detailed Drug Profiles

Ozempic (Semaglutide) - Diabetes Formulation

FDA-Approved Uses

Ozempic is FDA-approved exclusively for the treatment of type 2 diabetes in adults. While it shows weight loss effects, it is not approved specifically for weight management in non-diabetic patients. However, off-label prescribing for weight loss has become increasingly common.

Pricing Information (2026)

Retail Price (Without Insurance): $900-$1,100 per month

With Insurance Coverage: $50-$250 per month (copay varies by plan)

With GoodRx/Manufacturer Coupons: $400-$700 per month

Note: Novo Nordisk offers patient assistance programs for eligible patients, potentially reducing costs to $99-$199 monthly.

Weight Loss Efficacy

In clinical trials, Ozempic (at higher doses used off-label for weight loss) demonstrated average weight loss of 4-6% of body weight. When used at maximum diabetes doses, weight loss tends to be lower than dedicated weight loss formulations. Patients using Ozempic at weight management doses may see results comparable to Wegovy.

Common Side Effects

Insurance Coverage

Coverage Strategy: Most insurance plans cover Ozempic for diabetes. If using off-label for weight loss, coverage is less certain. Request "medical necessity" documentation from your doctor. Emphasize any obesity-related conditions like hypertension, sleep apnea, or metabolic syndrome. Many plans now approve for weight loss if BMI exceeds 30 (or 27 with comorbidities).

Wegovy (Semaglutide) - Weight Loss Formulation

FDA-Approved Uses

Wegovy is specifically FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as hypertension, type 2 diabetes, or cardiovascular disease. This dedicated approval makes insurance coverage more straightforward.

Pricing Information (2026)

Retail Price (Without Insurance): $1,200-$1,550 per month

With Insurance Coverage: $0-$500 per month (increasingly covered by major insurers)

With GoodRx/Manufacturer Coupons: $700-$950 per month

Manufacturer Support: Novo Nordisk's Wegovy Savings Program offers up to $500/month discount for uninsured patients, making out-of-pocket costs potentially $200-$300 monthly.

Weight Loss Efficacy

Wegovy clinical trials (STEP studies) showed remarkable results with average weight loss of 10-15% of body weight over 68 weeks of treatment. Some patients achieved weight loss exceeding 20% in extended trials. Results are more pronounced at higher maintenance doses (2.4mg weekly).

Common Side Effects

Insurance Coverage

Coverage Strategy: Insurance coverage for Wegovy has expanded significantly in 2025-2026. Most major plans (UnitedHealthcare, Aetna, Cigna, Humana, Blue Cross) now cover it with a prior authorization. Typically requires: BMI ≥30 or ≥27 with comorbidities, documented weight loss attempts, and 6-month behavioral program participation. Submit documentation from your physician demonstrating medical necessity.

Mounjaro (Tirzepatide) - Diabetes Formulation

FDA-Approved Uses

Mounjaro is FDA-approved for type 2 diabetes management in adults. As a dual GIP/GLP-1 receptor agonist, it offers a novel mechanism compared to semaglutide, providing potentially greater weight loss effects at diabetes doses. Like Ozempic, it's not officially approved for non-diabetic weight loss, though off-label use is increasing.

Pricing Information (2026)

Retail Price (Without Insurance): $1,000-$1,300 per month

With Insurance Coverage: $50-$300 per month (copay varies)

With GoodRx/Manufacturer Coupons: $550-$850 per month

Manufacturer Assistance: Eli Lilly's Mounjaro Savings Program provides up to $150/month copay card for eligible insured patients, or up to $500/month discount for uninsured patients.

Weight Loss Efficacy

Mounjaro demonstrates superior weight loss compared to semaglutide GLP-1 alone in head-to-head trials. Average weight loss is 6-8% at diabetes doses, with some studies showing comparable or superior results to GLP-1 monotherapy. The dual mechanism (GIP + GLP-1) may explain enhanced effectiveness.

Common Side Effects

Insurance Coverage

Coverage Strategy: Mounjaro typically has strong coverage for diabetes management through most insurance plans. For off-label weight loss use, the approval strategy is similar to Ozempic: document medical necessity, obesity-related comorbidities, and documented weight loss attempts. Tirzepatide's newer status means some plans may have stricter criteria or step therapy requirements.

Zepbound (Tirzepatide) - Weight Loss Formulation

FDA-Approved Uses

Zepbound received FDA approval in November 2023 specifically for chronic weight management in adults with obesity or overweight with weight-related conditions. It became the first and only GIP/GLP-1 receptor agonist approved exclusively for weight loss, providing a distinct advantage in insurance coverage and clinical positioning.

Pricing Information (2026)

Retail Price (Without Insurance): $1,400-$1,700 per month

With Insurance Coverage: $0-$550 per month (coverage rapidly expanding)

With GoodRx/Manufacturer Coupons: $850-$1,200 per month

Manufacturer Support: Eli Lilly's Zepbound Savings Program offers eligible uninsured patients $200/month maximum out-of-pocket cost, with potential additional savings for insured patients with copays exceeding that amount.

Weight Loss Efficacy

Zepbound demonstrates the most impressive weight loss results among available GLP-1/GIP medications. Clinical trials showed average weight loss of 20-22% of body weight over 72 weeks. In the Phase 3 SURMOUNT trials, patients taking tirzepatide achieved weight loss exceeding 25% in many cases. This superior efficacy represents a significant advancement in pharmacological weight management.

Common Side Effects